Nxera Pharma Co., Ltd. (SOLTF)
USD 6.75
(-0.88%)
USD 6.75
(-0.88%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 12.76 Billion | 15.56 Billion | 17.71 Billion | 8.84 Billion | 9.72 Billion | 3.82 Billion |
| Cost of Revenue | 3.1 Billion | 926 Million | 933 Million | 761 Million | 851 Million | 1.81 Billion |
| Gross Profit | 9.66 Billion | 14.64 Billion | 16.77 Billion | 8.08 Billion | 8.87 Billion | 2.01 Billion |
| Operating Expenses | 19.19 Billion | 11.2 Billion | 13 Billion | 7.15 Billion | 8.49 Billion | 9.41 Billion |
| Selling, General and Administrative Expenses | 9.96 Billion | 4.37 Billion | 3.94 Billion | 3.43 Billion | 3.61 Billion | 2.23 Billion |
| Research and Development Expenses | 10.07 Billion | 7.45 Billion | 5.93 Billion | 3.79 Billion | 4.29 Billion | 7.17 Billion |
| Other Expenses | -850 Million | - | - | - | - | - |
| Cost and Expenses | 22.29 Billion | 12.13 Billion | 13.93 Billion | 7.91 Billion | 9.34 Billion | 11.23 Billion |
| Operating Income | -9.52 Billion | 3.43 Billion | 3.77 Billion | 928 Million | 384 Million | -7.4 Billion |
| Interest Expense | 2.49 Billion | 756 Million | 3.79 Billion | 578 Million | 493 Million | - |
| Income Tax Expense | -3.48 Billion | 696 Million | -584 Million | 143 Million | -898 Million | -1.68 Billion |
| Earnings before Tax | -10.68 Billion | 1.07 Billion | 433 Million | 1.62 Billion | 534 Million | -9.63 Billion |
| Net Income | -7.19 Billion | 382 Million | 1.01 Billion | 1.47 Billion | 1.43 Billion | -7.94 Billion |
| Earnings Per Share Basic | -87.18 | 4.67 | 12.53 | 18.78 | 18.69 | -104.24 |
| Earnings Per Share Diluted | -87.17 | 4.63 | 12.40 | 18.61 | 18.48 | -104.24 |
| Weighted Average Shares Outstanding | 82.5 Million | 81.78 Million | 81.18 Million | 78.73 Million | 76.62 Million | 76.23 Million |
| Weighted Average Shares Outstanding (Diluted) | 82.51 Million | 82.59 Million | 82 Million | 79.49 Million | 77.48 Million | 76.23 Million |
| Gross Margin | 0.76 | 0.94 | 0.95 | 0.91 | 0.91 | 0.53 |
| EBIT Margin | -0.52 | 0.32 | 0.30 | 0.40 | 0.26 | -1.57 |
| Profit Margin | -0.56 | 0.02 | 0.06 | 0.17 | 0.15 | -2.08 |
| EBITDA | -6.58 Billion | 4.15 Billion | 8.18 Billion | 2.2 Billion | 2.44 Billion | -6.75 Billion |
| Earnings Before Tax Margin | -0.75 | 0.22 | 0.21 | 0.10 | 0.04 | -1.93 |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 FY | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Revenue | 8.1 Billion | 4.61 Billion | 7.29 Billion | 12.76 Billion | 3.32 Billion | 1.2 Billion |
| Cost of Revenue | 3.3 Billion | 2.17 Billion | 2.52 Billion | 4.9 Billion | 1.12 Billion | 133 Million |
| Gross Profit | 4.8 Billion | 2.43 Billion | 4.77 Billion | 7.86 Billion | 2.2 Billion | 1.07 Billion |
| Operating Expenses | 5.69 Billion | 5.83 Billion | 6.25 Billion | 16.92 Billion | 6.02 Billion | 3.27 Billion |
| Selling, General and Administrative Expenses | 3.36 Billion | 2.66 Billion | 3.19 Billion | - | 3.44 Billion | 1.46 Billion |
| Research and Development Expenses | 2.32 Billion | 3.16 Billion | 3.06 Billion | - | 2.97 Billion | 2.08 Billion |
| Other Expenses | -310 Million | - | - | - | - | - |
| Cost and Expenses | 8.99 Billion | 8 Billion | 8.77 Billion | 21.82 Billion | 7.15 Billion | 3.4 Billion |
| Operating Income | -888 Million | -3.39 Billion | -1.48 Billion | -9.06 Billion | -3.45 Billion | -2.2 Billion |
| Interest Expense | 199 Million | 185 Million | 1.63 Billion | 2.49 Billion | 646 Million | 196 Million |
| Income Tax Expense | 1.06 Billion | 485 Million | -2.6 Billion | -3.48 Billion | 820 Million | -1.23 Billion |
| Earnings before Tax | -362 Million | -2.79 Billion | -2.81 Billion | -10.68 Billion | -4.1 Billion | -1.89 Billion |
| Net Income | -1.42 Billion | -3.28 Billion | -208 Million | -7.19 Billion | -4.92 Billion | -658 Million |
| Earnings Per Share Basic | -15.86 | -36.68 | -2.33 | - | -59.82 | -8.01 |
| Earnings Per Share Diluted | -15.86 | -36.68 | -2.33 | - | -59.82 | -8.01 |
| Weighted Average Shares Outstanding | 89.67 Million | 89.44 Million | 89.44 Million | 82.51 Million | 82.33 Million | 82.12 Million |
| Weighted Average Shares Outstanding (Diluted) | 89.67 Million | 89.44 Million | 89.44 Million | 82.51 Million | 82.33 Million | 82.12 Million |
| Gross Margin | 0.59 | 0.53 | 0.65 | 0.62 | 0.66 | 0.89 |
| EBIT Margin | 0.01 | -0.52 | -0.07 | - | -0.80 | -1.11 |
| Profit Margin | -0.18 | -0.71 | -0.03 | -0.56 | -1.48 | -0.55 |
| EBITDA | 116 Million | -2.41 Billion | -500 Million | - | -2.66 Billion | -1.33 Billion |
| Earnings Before Tax Margin | -0.11 | -0.74 | -0.20 | -0.71 | -1.04 | -1.83 |
2323
002225
HEUBACHIND
1155
1632
8071